S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Better Than Oil Stocks (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Better Than Oil Stocks (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Better Than Oil Stocks (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Better Than Oil Stocks (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Better Than Oil Stocks (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Better Than Oil Stocks (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Better Than Oil Stocks (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Better Than Oil Stocks (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
NASDAQ:FDMT

4D Molecular Therapeutics (FDMT) Stock Forecast, Price & News

$12.73
+0.09 (+0.71%)
(As of 09/29/2023 ET)
Compare
Today's Range
$12.37
▼
$13.00
50-Day Range
$12.64
▼
$18.49
52-Week Range
$6.58
▼
$26.49
Volume
471,197 shs
Average Volume
367,456 shs
Market Capitalization
$535.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.25
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

4D Molecular Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
184.8% Upside
$36.25 Price Target
Short Interest
Bearish
8.77% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.32mentions of 4D Molecular Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.89) to ($3.10) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.35 out of 5 stars

Medical Sector

934th out of 972 stocks

Biological Products, Except Diagnostic Industry

149th out of 152 stocks

See Top Rated MarketRank™ Stocks Here

FDMT stock logo

About 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has product candidates that are in clinical trials, such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy. Its product candidates also include 4D-150 for the treatment of wet age-related macular degeneration and diabetic macular edema; and 4D-710 for the treatment of cystic fibrosis lung disease. In addition, the company has two product candidates that are in preclinical development stage, such as 4D-175 for the treatment of geographic atrophy; and 4D-725 for the treatment of alpha-1 antitrypsin deficiency lung disease. It has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

FDMT Price History

FDMT Stock News Headlines

September 25, 2023 | msn.com
4D Molecular Therapeutics: Some Failures, A Few Key Successes
September 14, 2023 | finanznachrichten.de
4D Molecular Therapeutics, Inc.: 4DMT Appoints Uneek Mehra as Chief Financial and Business Officer
October 1, 2023 | Behind the Markets (Ad)
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company
Decades of pent-up demand for this "first-ever" treatment could give you WINDFALL PROFITS... Click here to learn more >>>
September 7, 2023 | finance.yahoo.com
4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMD
September 7, 2023 | finance.yahoo.com
4DMT to Participate in Upcoming Investor Conferences
August 9, 2023 | finance.yahoo.com
4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights
August 9, 2023 | finance.yahoo.com
Despite currently being unprofitable, 4D Molecular Therapeutics (NASDAQ:FDMT) has delivered a 59% return to shareholders over 1 year
July 31, 2023 | markets.businessinsider.com
What 6 Analyst Ratings Have To Say About 4D Molecular Therapeutics
October 1, 2023 | Behind the Markets (Ad)
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company
Decades of pent-up demand for this "first-ever" treatment could give you WINDFALL PROFITS... Click here to learn more >>>
July 31, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Its Buy Rating for 4D Molecular Therapeutics (FDMT)
July 29, 2023 | finance.yahoo.com
4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023
July 17, 2023 | finance.yahoo.com
4DMT Completes Enrollment of Phase 2 PRISM Clinical Trial for Intravitreal 4D-150 in Patients with Wet AMD and Reports Interim Safety and Tolerability Data
July 14, 2023 | markets.businessinsider.com
SVB Securities Keeps Their Hold Rating on 4D Molecular Therapeutics (FDMT)
July 10, 2023 | seekingalpha.com
4D Molecular Therapeutics: Pioneering Gene Therapies And An Impressive Fiscal Performance
June 9, 2023 | msn.com
B of A Securities Maintains 4D Molecular Therapeutics (FDMT) Buy Recommendation
June 8, 2023 | markets.businessinsider.com
4D Molecular Therapeutics Stock Is Trading Higher Today - Here's Why
June 7, 2023 | finance.yahoo.com
4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting
June 7, 2023 | finance.yahoo.com
Andreas Halvorsen's Firm Storms Deeper Into 4D Molecular Therapeutics
June 3, 2023 | morningstar.com
4D Molecular Therapeutics Inc Ordinary Shares
May 24, 2023 | finance.yahoo.com
4DMT to Present Interim Data from 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis Lung Disease at the European Cystic Fibrosis Society (ECFS) 46th Annual Meeting
May 24, 2023 | markets.businessinsider.com
4D Molecular Therapeutics (FDMT) Gets a Buy from BMO Capital
May 12, 2023 | finance.yahoo.com
Andreas Halvorsen's Firm Packs Further Into 4D Molecular Therapeutics
May 11, 2023 | finance.yahoo.com
4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
May 10, 2023 | finance.yahoo.com
4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
May 9, 2023 | finance.yahoo.com
4D Molecular Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 8, 2023 | finance.yahoo.com
4D Molecular Therapeutics, Inc. (FDMT) Surges 5.4%: Is This an Indication of Further Gains?
May 5, 2023 | seekingalpha.com
4D Molecular Therapeutics prices $120M share offering
See More Headlines
Receive FDMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 4D Molecular Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FDMT Company Calendar

Last Earnings
8/09/2023
Today
9/30/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FDMT
CUSIP
N/A
CIK
1650648
Web
www.4dmoleculartherapeutics.com
Phone
510-505-2680
Fax
N/A
Employees
137
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$36.25
High Stock Price Forecast
$68.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+184.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.28)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-107,490,000.00
Net Margins
-4,876.01%
Pretax Margin
-4,876.01%
Return on Equity
-43.40%
Return on Assets
-39.13%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
23.11
Quick Ratio
23.11

Sales & Book Value

Annual Sales
$2.29 million
Price / Sales
234.28
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.14 per share
Price / Book
1.78

Miscellaneous

Outstanding Shares
42,053,000
Free Float
37,553,000
Market Cap
$535.33 million
Optionable
Not Optionable
Beta
2.37
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. John F. Milligan Ph.D. (Age 62)
    Exec. Chairman
    Comp: $150k
  • Dr. David H. Kirn M.D. (Age 61)
    Co-Founder, CEO & Director
    Comp: $920.97k
  • Dr. Fariborz Kamal Ph.D. (Age 60)
    Pres & COO
    Comp: $678.4k
  • Ms. Theresa Janke (Age 48)
    Co-Founder & Chief of Staff
  • Mr. Uneek Mehra (Age 51)
    Chief Financial & Bus. Officer
  • Mike Zanoni
    VP of Investor Relations
  • Dr. Scott P. Bizily J.D. (Age 51)
    Ph.D., Chief Legal & HR Officer and Corp. Sec.
  • Dr. Robert Y. Kim M.B.A. (Age 62)
    M.D., Chief Medical Officer
  • Dr. An Song Ph.D.
    Chief Devel. Officer
  • Ms. Karen S. Carothers (Age 72)
    Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













FDMT Stock - Frequently Asked Questions

Should I buy or sell 4D Molecular Therapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 4D Molecular Therapeutics in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" FDMT shares.
View FDMT analyst ratings or view top-rated stocks.

What is 4D Molecular Therapeutics' stock price forecast for 2023?

6 brokers have issued 1 year price targets for 4D Molecular Therapeutics' shares. Their FDMT share price forecasts range from $13.00 to $68.00. On average, they expect the company's share price to reach $36.25 in the next year. This suggests a possible upside of 184.8% from the stock's current price.
View analysts price targets for FDMT or view top-rated stocks among Wall Street analysts.

How have FDMT shares performed in 2023?

4D Molecular Therapeutics' stock was trading at $22.21 at the start of the year. Since then, FDMT stock has decreased by 42.7% and is now trading at $12.73.
View the best growth stocks for 2023 here.

When is 4D Molecular Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our FDMT earnings forecast.

How were 4D Molecular Therapeutics' earnings last quarter?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) announced its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.77) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.77). The company earned $0.24 million during the quarter, compared to analyst estimates of $1.43 million. 4D Molecular Therapeutics had a negative trailing twelve-month return on equity of 43.40% and a negative net margin of 4,876.01%.

What ETFs hold 4D Molecular Therapeutics' stock?

ETFs with the largest weight of 4D Molecular Therapeutics (NASDAQ:FDMT) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON).Invesco Dorsey Wright Healthcare Momentum ETF (PTH).

When did 4D Molecular Therapeutics IPO?

(FDMT) raised $101 million in an IPO on Friday, December 11th 2020. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, Evercore ISI and William Blair served as the underwriters for the IPO and Chardan was co-manager.

What is 4D Molecular Therapeutics' stock symbol?

4D Molecular Therapeutics trades on the NASDAQ under the ticker symbol "FDMT."

How do I buy shares of 4D Molecular Therapeutics?

Shares of FDMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 4D Molecular Therapeutics' stock price today?

One share of FDMT stock can currently be purchased for approximately $12.73.

How much money does 4D Molecular Therapeutics make?

4D Molecular Therapeutics (NASDAQ:FDMT) has a market capitalization of $535.33 million and generates $2.29 million in revenue each year. The company earns $-107,490,000.00 in net income (profit) each year or ($3.28) on an earnings per share basis.

How many employees does 4D Molecular Therapeutics have?

The company employs 137 workers across the globe.

How can I contact 4D Molecular Therapeutics?

The official website for the company is www.4dmoleculartherapeutics.com. The company can be reached via phone at 510-505-2680 or via email at mzanoni@4dmt.com.

This page (NASDAQ:FDMT) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -